載入中
NASDAQHealthcareMedical - Devices
最新資料
US$1.30
−US$0.12 · -8.45%
Profusa, Inc., a digital health technology company, develops bioengineered sensors for body to detect and continuously transmit clinical-grade data for personal and medical use in the United States. It offers the Lumee Oxygen Platform to monitor compromised tissue for peripheral artery disease, chronic wounds, and reconstructive surgery. The company researches and develops the Lumee Glucose Platform which is designed to monitor glucose levels in interstitial fluid. Profusa, Inc. is based in Berkeley, California.
前收盤價
US$1.30
−US$0.12 · -8.45%
盤前
US$1.32
+US$0.02 · +1.54%
10月13日 上午7:01 ET
盤中時間採用ET。市場資料可能有所延遲。
Profusa, Inc., a digital health technology company, develops bioengineered sensors for body to detect and continuously transmit clinical-grade data for personal and medical use in the United States. It offers the Lumee Oxygen Platform to monitor compromised tissue for peripheral artery disease, chronic wounds, and reconstructive surgery. The company researches and develops the Lumee Glucose Platform which is designed to monitor glucose levels in interstitial fluid. Profusa, Inc. is based in Berkeley, California.
日內區間
目前US$1.30
52週區間
目前US$1.30
盤中時間採用ET。市場資料可能有所延遲。
Profusa, Inc., a digital health technology company, develops bioengineered sensors for body to detect and continuously transmit clinical-grade data for personal and medical use in the United States. It offers the Lumee Oxygen Platform to monitor compromised tissue for peripheral artery disease, chronic wounds, and reconstructive surgery. The company researches and develops the Lumee Glucose Platform which is designed to monitor glucose levels in interstitial fluid. Profusa, Inc. is based in Berkeley, California.
日內區間
目前US$1.30
52週區間
目前US$1.30
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 研究與開發 | 280.4萬 USD | 160.8萬 USD | 203.6萬 USD | 419.9萬 USD | 766.3萬 USD |
| 銷售、一般及管理費用 | 2490.2萬 USD | 299.2萬 USD | 407.9萬 USD | 524.4萬 USD | 476.9萬 USD |
| 營業費用 | 1322.3萬 USD | 450萬 USD | 607萬 USD | 1114萬 USD | 1169萬 USD |
| 利息支出 | 509.5萬 USD | 442.4萬 USD | 428.3萬 USD | 627萬 USD | 407.9萬 USD |
| 折舊和攤銷 | — | — | — | 72.4萬 USD | 118萬 USD |
| 營業利益 | −1322.3萬 USD | −450萬 USD | −607萬 USD | −1114萬 USD | −1169萬 USD |
| 淨利 | −3582.3萬 USD | −923萬 USD | −1028.1萬 USD | −2021.7萬 USD | −1031萬 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2026年8月17日 | 1:4 | — | — |
股票分割 | 2026年7月7日 | 1:25 | — | — |
股票分割 | 2026年2月9日 | 1:75 | — | — |
已生效 2026年8月17日
1:4
已生效 2026年7月7日
1:25
已生效 2026年2月9日
1:75
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
